Anzeige
Mehr »
Login
Donnerstag, 23.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Mit dieser Aktie könntest Du von der Cannabis-Legalisierungswelle profitieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
168 Leser
Artikel bewerten:
(0)

DPS Group and TRIA Congratulate Moderna on ISPE 2019 Facility of the Future Category Award

Moderna's cGMP clinical development manufacturing facility takes category win in the 2019 ISPE Facility of the Year Award Program

BOSTON, April 2, 2019 /PRNewswire/ -- DPS Group, a privately-owned, global consulting, engineering, procurement, construction management and validation firm serving high-tech process industries, and design affiliate TRIA, a partner-led architecture firm with a focus on science and technology organizations bringing new discoveries to the market, are proud to announce that their design of a new clinical development manufacturing facility for Moderna has won the ISPE 2019 Facility of the Year Award (FOYA) in the Facility of the Future category.

Moderna's new mRNA clinical development manufacturing facility in Norwood, Mass. has been named a finalist for ISPE's 2019 Facility of the Year Award (FOYA) and the winner in its Facility of the Future category.

ISPE's Facility of the Year Awards is the premier global awards program recognizing innovation and creativity in the pharmaceutical and biotechnology manufacturing industries. Announced today at the 2019 ISPE Europe Annual Conference in Dublin, Ireland, the award-winning projects set the standard for pharmaceutical facilities of the future by demonstrating excellence in facility design, construction, and operations. DPS and TRIA provided full architectural, engineering design, and project management services for Moderna's new 200,000 SF Current Good Manufacturing Practices (cGMP) mRNA clinical manufacturing facility in Norwood, Mass.

Moderna is a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients. The company's Norwood facility provides the capacity to develop materials for pre-clinical studies, as well as Phase 1 and Phase 2 clinical development programs. ISPE selected Moderna as the 2019 Facility of the Future Category Award winner for the potential impact on patients through accelerated delivery of a new category of medicines.

"We are delighted to have worked with Moderna to bring this new state-of-the-art facility to successful completion," said Frank Keogh, chief executive officer, DPS Group. "It is extremely gratifying to deliver on Moderna's vision for a digitally-enabled, flexible and scalable facility to develop innovative medicines for patients. DPS and TRIA warmly congratulate Moderna on winning this prestigious ISPE Facility of the Future Category Award."

About DPS Group
DPS Group is a global consulting, engineering, and construction management company, serving high-tech industries around the world. Visit: www.dpsgroupglobal.com.

About TRIA
TRIA combines a deep understanding of the unique needs of science-based organizations with experience constructing spaces and places that enable those organizations to meet their goals. Visit: https://tria.design.

DPS Group is a global engineering, consulting and project management company, serving high-tech industries around the world. For more information, please visit www.dpsgroupglogal.com

Photo - https://mma.prnewswire.com/media/845428/DPS_TRIA_Moderna_Campus.jpg
Logo - https://mma.prnewswire.com/media/717915/DPS_Logo.jpg

KI-Champions: 3 Top-Werte, die Ihr Portfolio revolutionieren
Fordern Sie jetzt den brandneuen kostenfreien Sonderreport an und erfahren Sie, wie Sie von den enormen Wachstumschancen im Bereich Künstliche Intelligenz profitieren können - 100 % kostenlos.
Hier klicken
© 2019 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.